formulations, thus eliminating most nutraceuticals. We limited our review to the English-language literature. We reviewed www.clini caltr ials.gov to identify phase 2 and 3 trials that may be far enough along to be US Food and Drug Administration (FDA)-approved and available by the time this guideline was published. A hierarchy of outcome measures assessing pain and function in OA was developed based on the published literature http://onlin elibr ary.wiley.com/doi/10.1002/art.41142/ abstract